StockMacro
Company, fund or insider

Help

Menu

Cytek Biosciences

$6.12 +54% in 6 monthsMarket cap $800.4M

CTKB on XNAS, Technology, Cytek Biosciences, Inc., job postings

Measures activity, not value. Not investment advice.

Quarterly revenue up only 1.8% to $53.2M while 12-month net loss reached $81.2M.

  • BadFree cash flow negative at -$13.5M over the last 12 months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.

Industry
Laboratory analytical instruments (Technology)
Employees
703
Website
cytekbio.com
Listed
Nasdaq, US
Last results
4 Nov 2026
Next results
expected around 12 Jan 2027 (an estimate: a year ago it reported on 13 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $53.2M, net loss $6.1M.
Quarter to 31 Dec 2021: revenue $38.9M, net income -$1.2MQuarter to 31 Dec 2021: revenue $38.9M, net income -$1.2MQuarter to 31 Mar 2022: revenue $35.1M, net income -$2.2MQuarter to 31 Mar 2022: revenue $35.1M, net income -$2.2MQuarter to 30 Jun 2022: revenue $40.2M, net income -$702KQuarter to 30 Jun 2022: revenue $40.2M, net income -$702KQuarter to 30 Sep 2022: revenue $40.5M, net income $1.6MQuarter to 30 Sep 2022: revenue $40.5M, net income $1.6MQuarter to 31 Dec 2022: revenue $48.3M, net income $3.7MQuarter to 31 Dec 2022: revenue $48.3M, net income $3.7MQuarter to 31 Mar 2023: revenue $37.1M, net income -$6.8MQuarter to 31 Mar 2023: revenue $37.1M, net income -$6.8MQuarter to 30 Jun 2023: revenue $49.7M, net income -$4.4MQuarter to 30 Jun 2023: revenue $49.7M, net income -$4.4MQuarter to 30 Sep 2023: revenue $48.0M, net income -$6.5MQuarter to 30 Sep 2023: revenue $48.0M, net income -$6.5MQuarter to 31 Dec 2023: revenue $58.2M, net income –Quarter to 31 Mar 2024: revenue $44.9M, net income -$6.2MQuarter to 31 Mar 2024: revenue $44.9M, net income -$6.2MQuarter to 30 Jun 2024: revenue $46.6M, net income -$10.4MQuarter to 30 Jun 2024: revenue $46.6M, net income -$10.4MQuarter to 30 Sep 2024: revenue $51.5M, net income $941KQuarter to 30 Sep 2024: revenue $51.5M, net income $941KQuarter to 31 Dec 2024: revenue $57.5M, net income –Quarter to 31 Mar 2025: revenue $41.5M, net income -$11.4MQuarter to 31 Mar 2025: revenue $41.5M, net income -$11.4MQuarter to 30 Jun 2025: revenue $45.6M, net income -$5.6MQuarter to 30 Jun 2025: revenue $45.6M, net income -$5.6MQuarter to 30 Sep 2025: revenue $52.3M, net income -$5.5MQuarter to 30 Sep 2025: revenue $52.3M, net income -$5.5MQuarter to 31 Dec 2025: revenue $62.1M, net income -$44.1MQuarter to 31 Dec 2025: revenue $62.1M, net income -$44.1MQuarter to 31 Mar 2026: revenue $44.1M, net income -$18.9MQuarter to 31 Mar 2026: revenue $44.1M, net income -$18.9MQuarter to 30 Jun 2026: revenue $48.1M, net income -$12.2MQuarter to 30 Jun 2026: revenue $48.1M, net income -$12.2MQuarter to 30 Sep 2026: revenue $53.2M, net income -$6.1MQuarter to 30 Sep 2026: revenue $53.2M, net income -$6.1M
31 Dec 2021RevenueNet incomeNet losstallest bar $62.1M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$53.2M-$6.1M
30 Jun 2026$48.1M-$12.2M
31 Mar 2026$44.1M-$18.9M
31 Dec 2025$62.1M-$44.1M
30 Sep 2025$52.3M-$5.5M
30 Jun 2025$45.6M-$5.6M
31 Mar 2025$41.5M-$11.4M
31 Dec 2024$57.5M–
30 Sep 2024$51.5M$941K
30 Jun 2024$46.6M-$10.4M
31 Mar 2024$44.9M-$6.2M
31 Dec 2023$58.2M–
30 Sep 2023$48.0M-$6.5M
30 Jun 2023$49.7M-$4.4M
31 Mar 2023$37.1M-$6.8M
31 Dec 2022$48.3M$3.7M
30 Sep 2022$40.5M$1.6M
30 Jun 2022$40.2M-$702K
31 Mar 2022$35.1M-$2.2M
31 Dec 2021$38.9M-$1.2M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $207.6M $196.8M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +5.5% +5.0%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$81.2M -$12.8M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 54.7% 53.5% 49.6%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -21.1% -16.2% -7.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -39.1% -6.5% -10.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -23.2% -17.0%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$13.5M -$5.9M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $66.8M $93.3M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.45
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $2.46
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 33.4
P/SPrice to sales: market cap divided by revenue of the last 12 months. 3.9 4.1
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 4.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.5 2.4

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Cytek BiosciencesCTKB (this company) $800.4Mloss3.9+5.5%-39.1%
Pacific Biosciences of CaliforniaPACB $508.9Mloss3.2+4.4%-81.3%
908 DevicesMASS $360.5Mloss5.5+14%-36.9%
Alamar BiosciencesALMR $1.8B––––
Nautilus BiotechnolgyNAUT $270.0Mloss–––
10x GenomicsTXG $6.8Bloss11.0-3.6%-10.8%

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+1.8%

$53.2M vs $52.3M (quarter ended 30 Sep 2026)

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-2.6%

150 13F filers vs 154

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

66%

86.7M shares held by 13F filers (30 Sep 2026) of 130.8M outstanding (31 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

3.1%

4.1M shares sold short (30 Oct 2026) of 130.8M outstanding (31 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

3.6

4.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-6.9%

4.4M shares sold short in the report before, 4.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

21%

21% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 49%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

13

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$2.3M

the 12 months before: $1.4M

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

20

20 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

20×

20 articles in the last 7 days; its usual week has 1.

Price $6.12 on 20 Nov 2026, +17% over 12 months (12-month range $3.35 to $6.32)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $97K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.
Revenue per quarter. Revenue $53.2M in the latest quarter, +1.8% on a year earlier.
Capital spending per quarter. Capital spending $1.5M in the latest quarter, +129% on a year earlier.
Institutional holders (13F filers). 150 13F filers reported holding it in the latest 13F quarter, +3.4% on a year earlier.
Federal obligations. Federal obligations: $2.6M published in the last 12 months, +132% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
15 Jul 20268-K and other filingsDirector or officer change
25 Jun 20268-K and other filingsDirector or officer change
2 Jun 20268-K and other filingsDirector or officer change
2 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Sep 20248-K and other filingsDirector or officer change
12 Sep 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Mar 20248-K and other filingsDirector or officer change
1 Mar 20248-K and other filingsReport will be filed late
27 Feb 20248-K and other filingsDirector or officer change
27 Feb 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 Nov 20238-K and other filingsReport will be filed late
1 Aug 2023Sharp changeShort interest spike: short interest spike, 11.5M vs usual 4.1M (2023-07-14); 3.6x the same period a year earlier
18 Jul 2023Sharp changeShort interest spike: short interest spike, 10.5M vs usual 3.9M (2023-06-30); 2.9x the same period a year earlier
30 May 2023Sharp changeShort interest spike: short interest spike, 11.2M vs usual 3.9M (2023-05-15); 2.5x the same period a year earlier
7 Mar 2023Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 6.5M vs usual 1.2M (2022-12-31); 5.0x the same period a year earlier
28 Feb 20238-K and other filingsCompleted an acquisition or asset sale
1 Nov 20228-K and other filingsDirector or officer change
1 Nov 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Mar 20228-K and other filingsDirector or officer change
6 Jan 20228-K and other filingsDirector or officer change
6 Jan 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Feb 2022: $19.8M published
Month from 1 Mar 2022: $28.8M published
Month from 1 Apr 2022: -$418K published
Month from 1 May 2022: -$359K published
Month from 1 Jun 2022: -$416K published
Month from 1 Jul 2022: -$460K published
Month from 1 Aug 2022: -$666K published
Month from 1 Sep 2022: -$550K published
Month from 1 Oct 2022: -$637K published
Month from 1 Nov 2022: -$873K published
Month from 1 Dec 2022: -$479K published
Month from 1 Jan 2023: -$472K published
Month from 1 Feb 2023: -$509K published
Month from 1 Mar 2023: -$447K published
Month from 1 Apr 2023: -$403K published
Month from 1 May 2023: -$398K published
Month from 1 Jun 2023: -$352K published
Month from 1 Jul 2023: -$372K published
Month from 1 Aug 2023: -$365K published
Month from 1 Sep 2023: -$286K published
Month from 1 Oct 2023: -$217K published
Month from 1 Nov 2023: -$228K published
Month from 1 Dec 2023: -$217K published
Month from 1 Mar 2024: -$270K published
Month from 1 Apr 2024: -$131K published
Month from 1 Jun 2025: $97K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 1 published
Quarter from 1 Jul 2022: 1 published
Quarter from 1 Oct 2022: 1 published
Quarter from 1 Apr 2023: 1 published
Quarter from 1 Jul 2023: 3 published
Quarter from 1 Apr 2024: 2 published
Quarter from 1 Oct 2024: 1 published
Quarter from 1 Jan 2025: 2 published
Quarter from 1 Jul 2025: 1 published
Revenue per quarter
Quarter ended 31 Dec 2020: $30.6M; public on 18 Mar 2022
Quarter ended 31 Mar 2021: $24.3M; public on 13 May 2022
Quarter ended 31 Dec 2021: $38.9M, +27% on a year earlier; public on 18 Mar 2022
Quarter ended 31 Mar 2022: $35.1M, +44% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $40.2M, +32% on a year earlier; public on 11 Aug 2022
Quarter ended 30 Sep 2022: $40.5M, +18% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $48.3M, +24% on a year earlier; public on 2 Mar 2023
Quarter ended 31 Mar 2023: $37.1M, +5.8% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $49.7M, +24% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $48.0M, +19% on a year earlier; public on 15 Nov 2023
Quarter ended 31 Dec 2023: $58.2M, +20% on a year earlier; public on 14 Mar 2024
Quarter ended 31 Mar 2024: $44.9M, +21% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $46.6M, -6.2% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $51.5M, +7.3% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $57.5M, -1.3% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $41.5M, -7.6% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $45.6M, -2.2% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $52.3M, +1.5% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $62.1M, +8.1% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $44.1M, +6.5% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $48.1M, +5.6% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $53.2M, +1.8% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2020: $203K; public on 18 Mar 2022
Quarter ended 31 Mar 2021: $509K; public on 13 May 2022
Quarter ended 31 Dec 2021: $1.3M, +538% on a year earlier; public on 18 Mar 2022
Quarter ended 31 Mar 2022: $780K, +53% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $1.3M, +6.2% on a year earlier; public on 11 Aug 2022
Quarter ended 30 Sep 2022: $1.1M, -15% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $6.5M, +404% on a year earlier; public on 2 Mar 2023
Quarter ended 31 Mar 2023: $505K, -35% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $1.3M, -1.1% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $1.3M, +20% on a year earlier; public on 15 Nov 2023
Quarter ended 31 Dec 2023: $1.5M, -77% on a year earlier; public on 14 Mar 2024
Quarter ended 31 Mar 2024: $567K, +12% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $1.1M, -20% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $1.0M, -24% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $894K, -40% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $849K, +50% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $1.6M, +50% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $657K, -35% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $1.0M, +12% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $2.2M, +155% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $2.2M, +41% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $1.5M, +129% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 44; public on 14 Feb 2022
31 Mar 2022 report: 70; public on 16 May 2022
30 Jun 2022 report: 81; public on 15 Aug 2022
30 Sep 2022 report: 81; public on 14 Nov 2022
31 Dec 2022 report: 95; public on 14 Feb 2023
31 Mar 2023 report: 99; public on 15 May 2023
30 Jun 2023 report: 94; public on 14 Aug 2023
30 Sep 2023 report: 97; public on 14 Nov 2023
31 Dec 2023 report: 98; public on 14 Feb 2024
31 Mar 2024 report: 117; public on 15 May 2024
30 Jun 2024 report: 121; public on 14 Aug 2024
30 Sep 2024 report: 132; public on 14 Nov 2024
31 Dec 2024 report: 150; public on 14 Feb 2025
31 Mar 2025 report: 154; public on 15 May 2025
30 Jun 2025 report: 149; public on 14 Aug 2025
30 Sep 2025 report: 145; public on 14 Nov 2025
31 Dec 2025 report: 151; public on 17 Feb 2026
31 Mar 2026 report: 162; public on 15 May 2026
30 Jun 2026 report: 154; public on 14 Aug 2026
30 Sep 2026 report: 150; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: $25K published
Month from 1 Jan 2022: $30K published
Month from 1 Feb 2022: $23K published
Month from 1 Mar 2022: $85K published
Month from 1 May 2022: $56K published
Month from 1 Jun 2022: $419K published
Month from 1 Jul 2022: $273K published
Month from 1 Aug 2022: $756K published
Month from 1 Sep 2022: $762K published
Month from 1 Oct 2022: $125K published
Month from 1 Dec 2022: $98K published
Month from 1 Jan 2023: $9K published
Month from 1 Feb 2023: $59K published
Month from 1 Mar 2023: $176K published
Month from 1 Apr 2023: $157K published
Month from 1 May 2023: $153K published
Month from 1 Jun 2023: $648K published
Month from 1 Jul 2023: $431K published
Month from 1 Aug 2023: $245K published
Month from 1 Sep 2023: $1.1M published
Month from 1 Oct 2023: $29K published
Month from 1 Nov 2023: $36K published
Month from 1 Dec 2023: -$15K published
Month from 1 Jan 2024: $67K published
Month from 1 Feb 2024: $206K published
Month from 1 Mar 2024: $377K published
Month from 1 Apr 2024: $204K published
Month from 1 May 2024: $157K published
Month from 1 Jun 2024: $290K published
Month from 1 Jul 2024: $482K published
Month from 1 Aug 2024: $38K published
Month from 1 Sep 2024: $52K published
Month from 1 Oct 2024: $92K published
Month from 1 Nov 2024: $185K published
Month from 1 Dec 2024: $97K published
Month from 1 Jan 2025: $108K published
Month from 1 Feb 2025: $36K published
Month from 1 Mar 2025: $305K published
Month from 1 Apr 2025: $133K published
Month from 1 May 2025: $168K published
Month from 1 Jun 2025: $118K published
Month from 1 Jul 2025: $91K published
Month from 1 Aug 2025: $13K published
Month from 1 Sep 2025: $11K published
Month from 1 Oct 2025: $19K published
Month from 1 Dec 2025: $23K published
Month from 1 Jan 2026: $83K published
Month from 1 Feb 2026: $38K published
Month from 1 Mar 2026: $384K published
Month from 1 Apr 2026: $152K published
Month from 1 May 2026: $116K published
Month from 1 Jun 2026: $69K published
Month from 1 Jul 2026: $565K published
Month from 1 Aug 2026: $771K published
Month from 1 Sep 2026: $226K published
Month from 1 Oct 2026: $72K published
Month from 1 Nov 2026: $55K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $97K (3 Jun 2025), higher than 89% of its own history.
  • Insider net buying (open market): Insiders bought a net $0 in the last 12 months (the 12 months before: $97K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.
  • Revenue per quarter: Revenue $53.2M in the latest quarter, +1.8% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 83 insider trades

No trades in the last 90 days; the latest was filed 3 Jun 2025. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
3 Jun 2025William D. McCombeChief Financial OfficerBuy35,000$2.78$97KForm 4
23 Apr 2024Ming YanCHIEF TECHNOLOGY OFFICERSellplanned in advance (10b5-1)20,000$5.87$117KForm 4
11 Apr 2024Ming YanCHIEF TECHNOLOGY OFFICERSell1,900$7.00$13KForm 4
19 Mar 2024Ming YanCHIEF TECHNOLOGY OFFICERSellplanned in advance (10b5-1)40,000$6.74$270KForm 4
27 Dec 2023Patrik JeanmonodChief Financial OfficerSellplanned in advance (10b5-1)3,000$9.50$28KForm 4
21 Dec 2023Ming YanChief Technology OfficerSell20,000$9.43$189KForm 4
27 Nov 2023Patrik JeanmonodChief Financial OfficerSell3,000$6.94$21KForm 4
21 Nov 2023Ming YanChief Technology OfficerSellafter exercising options20,000$6.03$121KForm 4

150 institutions reported shares at the end of Q3 2026, 66% of the shares outstanding; 19 opened a position, 20 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.12.2M9.32%$72.6M+2.6M+27%
Millennium Management LLC7.3M5.57%$43.4M-2.1M-22%
HHLR Advisors, Ltd.6.7M5.09%$39.7MNo change
Boston Partners6.5M4.99%$38.9M-1.1M-15%
Topline Capital Management, LLC6.5M4.99%$38.9M+241K+3.8%
Vanguard Capital Management LLC4.9M3.74%$29.1M-53K-1.1%
Geode Capital Management, LLC3.1M2.34%$18.3M+7,283+0.2%
Acadian Asset Management LLC2.7M2.08%+1.3M+98%
Dimensional Fund Advisors LP2.6M1.96%$15.3M-49K-1.9%
State Street Corp2.6M1.95%$15.2M-13K-0.5%

Company events

All 18 company events

In 12 months: 3 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
15 Jul 2026Director or officer change8-K
25 Jun 2026Director or officer change8-K
2 Jun 2026Director or officer change8-K
12 Sep 2024Director or officer change8-K
19 Mar 2024Director or officer change8-K
1 Mar 2024Annual report will be filed lateNT 10-K
27 Feb 2024Director or officer change8-K
13 Nov 2023Quarterly report will be filed lateNT 10-Q

13 open postings; careers site tracked since 21 Nov 2026. Most in Field service & installation 23%, Corporate IT 23%, Executive & administrative support 8%, Chip design (ASIC / RTL / verification / physical design) 8%.

PostedJobLocation
16 Nov 2026Sr. Product Manager, Instruments and SoftwareProduct managementFremont, CA, US
9 Nov 2026Sr. Business Systems Analyst, NetSuiteCorporate ITFremont, CA, US
5 Nov 2026Manager, Electronics & FirmwareEmbedded & firmwareBellevue, WA, US
5 Nov 2026Staff FPGA EngineerChip design (ASIC / RTL / verification / physical design)Bellevue, WA, US
29 Oct 2026Associate/ Deputy General CounselLegal, policy & complianceFremont, CA, US
28 Oct 2026Administrative AssistantExecutive & administrative supportBellevue, WA, US
28 Oct 2026Sr. Business Systems Analyst, CRM (Salesforce)Corporate ITFremont, CA, US
28 Oct 2026Field Service Engineer, New YorkField service & installationUS

The 5 newest of 80 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 15 Jul 2026Filings record

    Director or officer change

  2. 25 Jun 2026Filings record

    Director or officer change

  3. 2 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 2 Jun 2026Filings record

    Director or officer change

  5. 4 Jun 2025Insiders record

    McCombe William D. (Chief Financial Officer) bought 35,000 shares of CTKB ($97,300) (dated 3 Jun 2025)

  6. 12 Sep 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  7. 12 Sep 2024Filings record

    Director or officer change

  8. 19 Mar 2024Filings record

    Director or officer change

  9. 1 Mar 2024Filings record

    Report will be filed late

  10. 27 Feb 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  11. 27 Feb 2024Filings record

    Director or officer change

  12. 13 Nov 2023Filings record

    Report will be filed late

  13. 26 Jul 2023Short interest and volume change

    had 11.5M shares sold short in the 14 Jul 2023 report, 3.6× the same report last year.

    Same report last year: 3.2M; its normal report is 4.1M.

    See the evidence
    This period
    11.5M (the 14 Jul 2023 report)
    Normal report (median of 24 earlier)
    4.1M
    Typical spread (median absolute deviation)
    1.3M
    How far from its usual level
    +3.8
    Same report last year
    3.2M
    History used
    714 days
    2022-07-15: 3.2M2022-07-29: 3.1M2022-08-15: 2.8M2022-08-31: 2.7M2022-09-15: 2.8M2022-09-30: 4.2M2022-10-14: 3.8M2022-10-31: 3.3M2022-11-15: 2.8M2022-11-30: 2.9M2022-12-15: 3.5M2022-12-30: 3.6M2023-01-13: 4.0M2023-01-31: 5.1M2023-02-15: 5.5M2023-02-28: 5.7M2023-03-15: 5.8M2023-03-31: 5.6M2023-04-14: 6.5M2023-04-28: 6.7M2023-05-15: 11.2M2023-05-31: 8.7M2023-06-15: 9.4M2023-06-30: 10.5M2023-07-14: 11.5M
    the 14 Jul 2023 report24 earlier reportsnormal: 4.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 13 Jul 2023Short interest and volume change

    had 10.5M shares sold short in the 30 Jun 2023 report, 2.9× the same report last year.

    Same report last year: 3.6M; its normal report is 3.9M.

    See the evidence
    This period
    10.5M (the 30 Jun 2023 report)
    Normal report (median of 24 earlier)
    3.9M
    Typical spread (median absolute deviation)
    1.1M
    How far from its usual level
    +4.0
    Same report last year
    3.6M
    History used
    700 days
    2022-06-30: 3.6M2022-07-15: 3.2M2022-07-29: 3.1M2022-08-15: 2.8M2022-08-31: 2.7M2022-09-15: 2.8M2022-09-30: 4.2M2022-10-14: 3.8M2022-10-31: 3.3M2022-11-15: 2.8M2022-11-30: 2.9M2022-12-15: 3.5M2022-12-30: 3.6M2023-01-13: 4.0M2023-01-31: 5.1M2023-02-15: 5.5M2023-02-28: 5.7M2023-03-15: 5.8M2023-03-31: 5.6M2023-04-14: 6.5M2023-04-28: 6.7M2023-05-15: 11.2M2023-05-31: 8.7M2023-06-15: 9.4M2023-06-30: 10.5M
    the 30 Jun 2023 report24 earlier reportsnormal: 3.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 25 May 2023Short interest and volume change

    had 11.2M shares sold short in the 15 May 2023 report, 2.5× the same report last year.

    Same report last year: 4.5M; its normal report is 3.9M.

    See the evidence
    This period
    11.2M (the 15 May 2023 report)
    Normal report (median of 24 earlier)
    3.9M
    Typical spread (median absolute deviation)
    855K
    How far from its usual level
    +5.8
    Same report last year
    4.5M
    History used
    654 days
    2022-05-13: 4.5M2022-05-31: 4.1M2022-06-15: 4.0M2022-06-30: 3.6M2022-07-15: 3.2M2022-07-29: 3.1M2022-08-15: 2.8M2022-08-31: 2.7M2022-09-15: 2.8M2022-09-30: 4.2M2022-10-14: 3.8M2022-10-31: 3.3M2022-11-15: 2.8M2022-11-30: 2.9M2022-12-15: 3.5M2022-12-30: 3.6M2023-01-13: 4.0M2023-01-31: 5.1M2023-02-15: 5.5M2023-02-28: 5.7M2023-03-15: 5.8M2023-03-31: 5.6M2023-04-14: 6.5M2023-04-28: 6.7M2023-05-15: 11.2M
    the 15 May 2023 report24 earlier reportsnormal: 3.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 7 Mar 2023Financials change

    spent $6.5M on capital projects in the quarter ended 31 Dec 2022, 5.0× the same quarter last year.

    Same quarter last year: $1.3M; its normal quarter is $1.2M.

    See the evidence
    This period
    $6.5M (the quarter ended 31 Dec 2022)
    Normal quarter (median of 8 earlier)
    $1.2M
    Typical spread (median absolute deviation)
    $138K
    How far from its usual level
    +5.3
    Same quarter last year
    $1.3M
    History used
    822 days
    2020-12-31: $203K2021-03-31: $509K2021-06-30: $1.3M2021-09-30: $1.3M2021-12-31: $1.3M2022-03-31: $780K2022-06-30: $1.3M2022-09-30: $1.1M2022-12-31: $6.5M
    the quarter ended 31 Dec 20228 earlier quartersnormal: $1.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  17. 28 Feb 2023Filings record

    Completed an acquisition or asset sale

  18. 1 Nov 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 1 Nov 2022Filings record

    Director or officer change

  20. 17 Mar 2022Insiders record

    RA Capital Healthcare Fund LP (director) and 4 other(s) bought 583,870 shares of CTKB ($7.2M) (dated 16 Mar 2022)

  21. 12 Mar 2022Insiders record

    Shah Rajeev M. (director) and 4 other(s) bought 634,638 shares of CTKB ($8.2M) (dated 11 Mar 2022)

  22. 9 Mar 2022Insiders record

    Shah Rajeev M. (director) and 4 other(s) bought 647,264 shares of CTKB ($8.2M) (dated 8 Mar 2022)

  23. 3 Mar 2022Insiders record

    Shah Rajeev M. (director) and 4 other(s) bought 441,865 shares of CTKB ($5.7M) (dated 2 Mar 2022)

  24. 2 Mar 2022Filings record

    Director or officer change

  25. 26 Feb 2022Insiders record

    RA Capital Nexus Fund II, L.P. (director) and 4 other(s) bought 420,380 shares of CTKB ($5.6M) (dated 25 Feb 2022)

  26. 23 Feb 2022Insiders record

    Shah Rajeev M. (director) and 4 other(s) bought 547,380 shares of CTKB ($7.7M) (dated 22 Feb 2022)

  27. 17 Feb 2022Insiders record

    RA CAPITAL MANAGEMENT, L.P. (director) and 4 other(s) bought 498,629 shares of CTKB ($7.4M) (dated 16 Feb 2022)

  28. 6 Jan 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  29. 6 Jan 2022Filings record

    Director or officer change

  30. 30 Jul 2021Insiders record

    Kolchinsky Peter (director) and 4 other(s) bought 2,950,000 shares of CTKB ($50.1M) (dated 29 Jul 2021)

  31. 28 Jul 2021Insiders change

    had 4 insiders buy $194K of its shares on the open market within 30 days (4 filings).

    Who bought: Dion Gisele, Poirson Allen, Barnett Valerie, Ball Jack.

    See the evidence (4 source records)
    Independent buyers
    4
    Purchase filings (Form 4, code P)
    4
    Total bought
    $194K
    Window
    28 Jun 2021 to 28 Jul 2021

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  32. 28 Jul 2021Insiders record

    Ball Jack (director) bought 3,000 shares of CTKB ($51,000) (dated 27 Jul 2021)

  33. 28 Jul 2021Insiders record

    Barnett Valerie (General Counsel) bought 1,900 shares of CTKB ($32,300) (dated 27 Jul 2021)

  34. 28 Jul 2021Insiders record

    Poirson Allen (SVP Marketing and Corp. Dev.) bought 1,500 shares of CTKB ($25,500) (dated 27 Jul 2021)

  35. 28 Jul 2021Insiders record

    Dion Gisele (director) bought 5,000 shares of CTKB ($85,000) (dated 27 Jul 2021)

  36. 19 Jul 2021Filings record

    Registered new securities for sale (S-1)

  37. 14 Jul 2021Filings record

    Registered new securities for sale (S-1) (dated 13 Jul 2021)

  38. 2 Jul 2021Filings record

    Registered new securities for sale (S-1)

  39. 10 Nov 2020Filings record

    Private placement of securities (Form D)

Not listed: 122 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001831915
Ticker
CTKB
Domain
cytekbio.com
Employer name
Cytek Biosciences, Inc. (1 unverified)
Hq location
CA|FREMONT|94538 (1 unverified)
Name
Cytek Biosciences Canada Ltd, Cytek Biosciences, Inc., Cytek Japan Corporation, Cytek Limited and 2 more
Uei
CF5TNJZGENJ3, GQC7U3N63LB9, TD2JM5U24NF8
  • DOL H-1B labor condition applications and PERM certifications79 data points2 Dec 2019 to 13 Jul 2026
  • SEC Form 13F institutional holdings189 data points30 Sep 2021 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)68 records10 Nov 2020 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)458 data points31 Dec 2019 to 31 Oct 2026
  • SEC Form 4 insider transactions83 records, 316 data points27 Jul 2021 to 3 Jun 2025
  • FINRA short interest (twice monthly)377 data points30 Jul 2021 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2680 data points23 Jul 2021 to 20 Nov 2026
  • USASpending.gov federal awards747 data points23 Dec 2015 to 29 Oct 2026